Business
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk
About this update from Veracyte, Inc.
[{"type":"text","content":"\nFindings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer\n\nData support Veracyte’s plan to expand test availability in the U.S. and offer test globally as an in vitro diagnostic\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company’s Decipher Prostate Genomic Classifier to identify men with advanced prostate cancer who are more likely to benefit from intensified treatment with abiraterone acetate and prednisolone (AAP) in addition to standard-of-care androgen-deprivation therapy (Abstract #13580). The findings were shared in an oral presentation today at the European Society for Medical Oncology (ESMO) Congress 2022 and support the company’s continued expansion of its high-value genomic tests for patients in the United States and globally.\n\n“There are an increasing number of treatment options available for men with advanced prostate cancer, and the challenge for physicians is determining the best treatment combination for the right patient,” said Gerhardt Attard, M.D., Ph.D., group leader of the Treatment Resistance Research Group at the University College London Cancer Institute, and STAMPEDE study co-investigator. “Our findings show that the Decipher Prostate Genomic Classifier – and tumor transcriptomes in general – can provide robust and clinically relevant prognostic information that may help guide important decisions about the treatment of advanced prostate cancer. Most notably, this study has identified patients who have poor prognoses and benefit greatly from addition of hormone treatment tablets, while other men have a good prognosis and may be able to avoid the toxicities of treatment.”\n\nThe Decipher Prostate classifier is a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment.\n\nThe STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) protocol involves more than 10,000 men to date with high-r...